61 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
statements of historical fact contained in this MD&A, including statements regarding our strategy, future operations, future financial position, future … with a variety of serious or life-threatening diseases using our innovative formulation of oxypurinol, and our proprietary pipeline-in-a-product strategy
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
proprietary pipeline-in-a-product strategy identifying potential product candidates and conducting preclinical studies and preparing for clinical … Practices (“cGMP”) requirements;
our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected … formulation of oxypurinol, and our proprietary pipeline-in-a-product strategy supported by our intellectual property, established exclusive manufacturing
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
statements of historical fact contained in this MD&A, including statements regarding our strategy, future operations, future financial position, future … with a variety of serious or life-threatening diseases using our innovative formulation of oxypurinol, and our proprietary pipeline-in-a-product strategy
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
proprietary pipeline-in-a-product strategy identifying potential product candidates and conducting preclinical studies and preparing for clinical … Practices (“cGMP”) requirements;
our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any
424B3
qb1gkf
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
wgqlgbg07vdhbfs3h4
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
gv1s8aks4ge x0t
8 Apr 24
XORTX Welcomes New Member to the Board of Directors
7:30am
424B5
pkqsthb 4h6k87ow0b
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
o1s714hay nueo99xxn
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
8rvh l3cj5js
25 Aug 23
Prospectus supplement
6:00am
424B3
dkoj9fhx8 pufx7
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
eaxlmps9mvb
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
xbti8nb2 qtjkz
14 Aug 23
Prospectus supplement
4:42pm
424B3
huqam2c evblmn2y28p
14 Aug 23
Prospectus supplement
4:40pm
POS AM
94b 31xmy
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm